minute, with a Betaplate scintillation counter (Pharmacia LKB Biotechnology Inc., Piscataway, N.J.). By 3 days postinfection, large cell clumps were evident only in cultures exposed to MPA concentrations of less than 1.0 ,uM, a concentration which inhibited thymidine uptake in both EBV-infected and uninfected cells ( Fig. 1; see below) .
Mycophenolic acid (MPA) noncompetitively inhibits IMP dehydrogenase, the rate-controlling enzyme for de novo biosynthesis of GMP, thus depleting cellular pools of GTP and dGTP (14, 26) . Because lymphoid cells cannot use the salvage pathway for purine synthesis (3), depletion of dGTP inhibits DNA replication (6, 21) . MPA was shown to inhibit proliferation of B and T lymphocytes in vitro and in vivo (2, (7) (8) (9) . While various human T-cell, B-cell, and promonocytic cell lines are highly sensitive to the cytostatic effects of MPA (2, 7), nonlymphoid cells, such as the K562 erythroleukemia line, are less susceptible (7) .
MPA and its ester derivative, mycophenolate mofetil, have significant immunosuppressive activity in animal transplant models (8, 9, [15] [16] [17] and are undergoing investigation in human organ transplantation, a setting in which EpsteinBarr virus (EBV) can produce lymphoproliferative disease (5, 11, 23, 27) . Since EBV infects, growth transforms, and replicates in B lymphocytes (for a review, see reference 12) , MPA Table 1 indicate that 2 to 5% and 1 to 2% of the cells expressed EBNA-2 and LMP-1, respectively, following a single round of cell division. This expression of EBNA-2 and LMP-1 was not affected by an MPA concentration of 0.1 or 0.01 ,uM. However, 1.0 ,uM MPA inhibited, but did not completely block, EBNA-2 and LMP-1 expression, thereby reducing the number of EBNA-2-and LMP-1-expressing cells to 1% or less. At concentrations higher than 1.0 ,uM MPA, no further reduction in EBNA-2 and LMP-1 expression was noted, indicating that even high concentrations of MPA could not completely block EBNA-2 and LMP-1 expression. A 50% reduction of EBNA-2 and LMP-1 fluorescence might be expected because of a nonspecific antiproliferative effect of MPA (see below), since the first round of cell division after EBV infection of B lymphocytes in vitro is between 36 and 72 h postinfection (1, 19, 25) . Since both EBNA-2 and LMP-1 are putative mediators of EBV-induced B-cell transformation (12), the inability of MPA to inhibit their expression completely might indicate that MPA cannot prevent initiation of the transforming process.
MPA concentrations of 1.0 ,uM and above inhibited the outgrowth of EBV-transformed cells (Fig. 1) . However, even this was likely due to an antiproliferative effect of MPA rather than an effect on EBV initiation or maintenance of transformation, since reversibility studies showed that treatment with 2. (Table 2) . At a uct, gp220. 1"I-labelled protein A (0.1 ,uCi/ml; Amersham) he cell number was added in a secondary step to bind the primary antibody. The lack of effect of MPA on EBV latent-or lytic-gene LMP-lC expression is surprising, particularly since lytic-gene expres- GTP from cellular pools, thereby enabling viral DNA synthesis to be unaffected by even high levels of MPA.
Because MPA does not inhibit EBV replication, any virus released in vivo could potentially continue to infect B cells, with resulting expression of EBNA-2 and LMP-1. These infected cells should not proliferate as long as therapeutic levels of MPA are present. Human renal allografts have been maintained in good functional condition for several years by using low doses of cyclosporine (thus reducing nephrotoxicity), mycophenolate mofetil, and low doses of prednisone (22) . In human liver allograft recipients, it has been possible to withdraw cyclosporine and maintain the grafts in good functional condition with mycophenolate mofetil and lowdose prednisone (10). Cyclosporine does not inhibit the outgrowth of EBV-transformed B cells but suppresses the T-cell-mediated surveillance that normally inhibits that outgrowth (18) . In contrast, MPA, in clinically attainable concentrations, inhibits the proliferation of EBV-transformed B cells. It is therefore reasonable to suggest that long-term maintenance therapy with mycophenolate mofetil, with or without cyclosporine, might reduce the risk of development of EBV-related lymphoproliferative disease.
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